“The inspection, which commenced on 10 February 2025 and concluded on 18 February 2025, resulted in seven minor observations, none of which pertain to the data integrity of the facility,” the company said in a statement. As a result, Orchid Pharma continues to hold its exclusive position as India’s only USFDA-approved manufacturing site for sterile cephalosporins, it added.
